CHEK1 and sarcoma: CHEK1 inhibition (e.g., prexasertib) abrogates S-phase checkpoint control and can precipitate replication catastrophe in RS-primed EwS cells, with robust preclinical activity and early clinical signals in translocation-driven sarcomas [78,79] (Table 2, CHEK1 targeting).